Observational studyNeurology2021
Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series.
Open access · bronzeAbstract readObservational Study
In one paragraph
Observational study in Neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
4.3field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Exploring the therapeutic potential of autologous hematopoietic stem cell transplantation in progressive multiple sclerosis-a systematic review.European journal of neurology · 2024Pooled it
- Mesenchymal stromal cell extracellular vesicles for multiple sclerosis in preclinical rodent models: A meta-analysis.Frontiers in immunology · 2022Pooled it
- Factors associated with outcomes following autologous haematopoietic stem cell transplantation for multiple sclerosis.Journal of neurology, neurosurgery, and psychiatry · 2025Article
- The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis.Brain : a journal of neurology · 2025Review
- Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study.Annals of neurology · 2025Observational
- Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT.Nature reviews. Neurology · 2025Review
- Skull and vertebral bone marrow in central nervous system inflammation.Fundamental research · 2024Review
- Enhanced and cross-reactiveFrontiers in immunology · 2024Article
- Stem cell therapies: a new era in the treatment of multiple sclerosis.Frontiers in neurology · 2024Review
- Review
- Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis: Recent Advances.Current neurology and neuroscience reports · 2023Review
- Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline.Therapeutic advances in neurological disorders · 2023Article
- Autologous Hematopoietic Stem-Cell Transplantation in Multiple Sclerosis: A Systematic Review and Meta-Analysis.Neurology and therapy · 2022Article
- B-Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2022Article
- Hematopoietic anomalies fuels multiple sclerosis.Life medicine · 2022Article
- The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.Journal of neurology · 2022Article
- Autologous haematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis.European journal of neurology · 2022Article
- Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis.Journal of neurology · 2022Article
- Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature.Journal of clinical medicine · 2022Review
- Immune Reconstitution Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: A Review on Behalf of the EBMT Autoimmune Diseases Working Party.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 3 countries.
Richard S NicholasFrom the Department of Brain Sciences (R.S.N., A.M., A.S., P.M.), Faculty of Medicine, and Centre for Haematology (E.O., I.G.), Faculty of Medicine, Imperial College London; Imperial College Healthcare NHS Trust (R.S.N., O.M., V.S.-C., A.S., E.O., I.G., P.M.); Department of Neurology (E.E.R., E.S.), King's College Hospital, London, UK; Department of Neurosciences, Drug and Child Health (A.M.), University of Florence, Italy; Barts Health NHS Trust (B.T.); Department of Haematological Medicine (V.M., M.A.K.), King's College Hospital NHS Foundation Trust; Queen Square MS Centre (O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK; Department of Health Sciences (DISSAL) (M.P.S.), University of Genova; and IRCCS Ospedale Policlinico San Martino (M.P.S.), Genova, Italy.ORCID 0000-0003-0414-1225
Elijah E RhoneFrom the Department of Brain Sciences (R.S.N., A.M., A.S., P.M.), Faculty of Medicine, and Centre for Haematology (E.O., I.G.), Faculty of Medicine, Imperial College London; Imperial College Healthcare NHS Trust (R.S.N., O.M., V.S.-C., A.S., E.O., I.G., P.M.); Department of Neurology (E.E.R., E.S.), King's College Hospital, London, UK; Department of Neurosciences, Drug and Child Health (A.M.), University of Florence, Italy; Barts Health NHS Trust (B.T.); Department of Haematological Medicine (V.M., M.A.K.), King's College Hospital NHS Foundation Trust; Queen Square MS Centre (O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK; Department of Health Sciences (DISSAL) (M.P.S.), University of Genova; and IRCCS Ospedale Policlinico San Martino (M.P.S.), Genova, Italy.
Alice MariottiniFrom the Department of Brain Sciences (R.S.N., A.M., A.S., P.M.), Faculty of Medicine, and Centre for Haematology (E.O., I.G.), Faculty of Medicine, Imperial College London; Imperial College Healthcare NHS Trust (R.S.N., O.M., V.S.-C., A.S., E.O., I.G., P.M.); Department of Neurology (E.E.R., E.S.), King's College Hospital, London, UK; Department of Neurosciences, Drug and Child Health (A.M.), University of Florence, Italy; Barts Health NHS Trust (B.T.); Department of Haematological Medicine (V.M., M.A.K.), King's College Hospital NHS Foundation Trust; Queen Square MS Centre (O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK; Department of Health Sciences (DISSAL) (M.P.S.), University of Genova; and IRCCS Ospedale Policlinico San Martino (M.P.S.), Genova, Italy.
Eli SilberFrom the Department of Brain Sciences (R.S.N., A.M., A.S., P.M.), Faculty of Medicine, and Centre for Haematology (E.O., I.G.), Faculty of Medicine, Imperial College London; Imperial College Healthcare NHS Trust (R.S.N., O.M., V.S.-C., A.S., E.O., I.G., P.M.); Department of Neurology (E.E.R., E.S.), King's College Hospital, London, UK; Department of Neurosciences, Drug and Child Health (A.M.), University of Florence, Italy; Barts Health NHS Trust (B.T.); Department of Haematological Medicine (V.M., M.A.K.), King's College Hospital NHS Foundation Trust; Queen Square MS Centre (O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK; Department of Health Sciences (DISSAL) (M.P.S.), University of Genova; and IRCCS Ospedale Policlinico San Martino (M.P.S.), Genova, Italy.
Omar MalikFrom the Department of Brain Sciences (R.S.N., A.M., A.S., P.M.), Faculty of Medicine, and Centre for Haematology (E.O., I.G.), Faculty of Medicine, Imperial College London; Imperial College Healthcare NHS Trust (R.S.N., O.M., V.S.-C., A.S., E.O., I.G., P.M.); Department of Neurology (E.E.R., E.S.), King's College Hospital, London, UK; Department of Neurosciences, Drug and Child Health (A.M.), University of Florence, Italy; Barts Health NHS Trust (B.T.); Department of Haematological Medicine (V.M., M.A.K.), King's College Hospital NHS Foundation Trust; Queen Square MS Centre (O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK; Department of Health Sciences (DISSAL) (M.P.S.), University of Genova; and IRCCS Ospedale Policlinico San Martino (M.P.S.), Genova, Italy.
Victoria Singh-CurryFrom the Department of Brain Sciences (R.S.N., A.M., A.S., P.M.), Faculty of Medicine, and Centre for Haematology (E.O., I.G.), Faculty of Medicine, Imperial College London; Imperial College Healthcare NHS Trust (R.S.N., O.M., V.S.-C., A.S., E.O., I.G., P.M.); Department of Neurology (E.E.R., E.S.), King's College Hospital, London, UK; Department of Neurosciences, Drug and Child Health (A.M.), University of Florence, Italy; Barts Health NHS Trust (B.T.); Department of Haematological Medicine (V.M., M.A.K.), King's College Hospital NHS Foundation Trust; Queen Square MS Centre (O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK; Department of Health Sciences (DISSAL) (M.P.S.), University of Genova; and IRCCS Ospedale Policlinico San Martino (M.P.S.), Genova, Italy.
Ben TurnerFrom the Department of Brain Sciences (R.S.N., A.M., A.S., P.M.), Faculty of Medicine, and Centre for Haematology (E.O., I.G.), Faculty of Medicine, Imperial College London; Imperial College Healthcare NHS Trust (R.S.N., O.M., V.S.-C., A.S., E.O., I.G., P.M.); Department of Neurology (E.E.R., E.S.), King's College Hospital, London, UK; Department of Neurosciences, Drug and Child Health (A.M.), University of Florence, Italy; Barts Health NHS Trust (B.T.); Department of Haematological Medicine (V.M., M.A.K.), King's College Hospital NHS Foundation Trust; Queen Square MS Centre (O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK; Department of Health Sciences (DISSAL) (M.P.S.), University of Genova; and IRCCS Ospedale Policlinico San Martino (M.P.S.), Genova, Italy.
Antonio ScalfariFrom the Department of Brain Sciences (R.S.N., A.M., A.S., P.M.), Faculty of Medicine, and Centre for Haematology (E.O., I.G.), Faculty of Medicine, Imperial College London; Imperial College Healthcare NHS Trust (R.S.N., O.M., V.S.-C., A.S., E.O., I.G., P.M.); Department of Neurology (E.E.R., E.S.), King's College Hospital, London, UK; Department of Neurosciences, Drug and Child Health (A.M.), University of Florence, Italy; Barts Health NHS Trust (B.T.); Department of Haematological Medicine (V.M., M.A.K.), King's College Hospital NHS Foundation Trust; Queen Square MS Centre (O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK; Department of Health Sciences (DISSAL) (M.P.S.), University of Genova; and IRCCS Ospedale Policlinico San Martino (M.P.S.), Genova, Italy.
Olga CiccarelliFrom the Department of Brain Sciences (R.S.N., A.M., A.S., P.M.), Faculty of Medicine, and Centre for Haematology (E.O., I.G.), Faculty of Medicine, Imperial College London; Imperial College Healthcare NHS Trust (R.S.N., O.M., V.S.-C., A.S., E.O., I.G., P.M.); Department of Neurology (E.E.R., E.S.), King's College Hospital, London, UK; Department of Neurosciences, Drug and Child Health (A.M.), University of Florence, Italy; Barts Health NHS Trust (B.T.); Department of Haematological Medicine (V.M., M.A.K.), King's College Hospital NHS Foundation Trust; Queen Square MS Centre (O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK; Department of Health Sciences (DISSAL) (M.P.S.), University of Genova; and IRCCS Ospedale Policlinico San Martino (M.P.S.), Genova, Italy.
Maria P SormaniFrom the Department of Brain Sciences (R.S.N., A.M., A.S., P.M.), Faculty of Medicine, and Centre for Haematology (E.O., I.G.), Faculty of Medicine, Imperial College London; Imperial College Healthcare NHS Trust (R.S.N., O.M., V.S.-C., A.S., E.O., I.G., P.M.); Department of Neurology (E.E.R., E.S.), King's College Hospital, London, UK; Department of Neurosciences, Drug and Child Health (A.M.), University of Florence, Italy; Barts Health NHS Trust (B.T.); Department of Haematological Medicine (V.M., M.A.K.), King's College Hospital NHS Foundation Trust; Queen Square MS Centre (O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK; Department of Health Sciences (DISSAL) (M.P.S.), University of Genova; and IRCCS Ospedale Policlinico San Martino (M.P.S.), Genova, Italy.
Eduardo OlavarriaFrom the Department of Brain Sciences (R.S.N., A.M., A.S., P.M.), Faculty of Medicine, and Centre for Haematology (E.O., I.G.), Faculty of Medicine, Imperial College London; Imperial College Healthcare NHS Trust (R.S.N., O.M., V.S.-C., A.S., E.O., I.G., P.M.); Department of Neurology (E.E.R., E.S.), King's College Hospital, London, UK; Department of Neurosciences, Drug and Child Health (A.M.), University of Florence, Italy; Barts Health NHS Trust (B.T.); Department of Haematological Medicine (V.M., M.A.K.), King's College Hospital NHS Foundation Trust; Queen Square MS Centre (O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK; Department of Health Sciences (DISSAL) (M.P.S.), University of Genova; and IRCCS Ospedale Policlinico San Martino (M.P.S.), Genova, Italy.
Varun MehraFrom the Department of Brain Sciences (R.S.N., A.M., A.S., P.M.), Faculty of Medicine, and Centre for Haematology (E.O., I.G.), Faculty of Medicine, Imperial College London; Imperial College Healthcare NHS Trust (R.S.N., O.M., V.S.-C., A.S., E.O., I.G., P.M.); Department of Neurology (E.E.R., E.S.), King's College Hospital, London, UK; Department of Neurosciences, Drug and Child Health (A.M.), University of Florence, Italy; Barts Health NHS Trust (B.T.); Department of Haematological Medicine (V.M., M.A.K.), King's College Hospital NHS Foundation Trust; Queen Square MS Centre (O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK; Department of Health Sciences (DISSAL) (M.P.S.), University of Genova; and IRCCS Ospedale Policlinico San Martino (M.P.S.), Genova, Italy.ORCID 0000-0001-6572-0971
Ian GabrielFrom the Department of Brain Sciences (R.S.N., A.M., A.S., P.M.), Faculty of Medicine, and Centre for Haematology (E.O., I.G.), Faculty of Medicine, Imperial College London; Imperial College Healthcare NHS Trust (R.S.N., O.M., V.S.-C., A.S., E.O., I.G., P.M.); Department of Neurology (E.E.R., E.S.), King's College Hospital, London, UK; Department of Neurosciences, Drug and Child Health (A.M.), University of Florence, Italy; Barts Health NHS Trust (B.T.); Department of Haematological Medicine (V.M., M.A.K.), King's College Hospital NHS Foundation Trust; Queen Square MS Centre (O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK; Department of Health Sciences (DISSAL) (M.P.S.), University of Genova; and IRCCS Ospedale Policlinico San Martino (M.P.S.), Genova, Italy.
Majid A KazmiFrom the Department of Brain Sciences (R.S.N., A.M., A.S., P.M.), Faculty of Medicine, and Centre for Haematology (E.O., I.G.), Faculty of Medicine, Imperial College London; Imperial College Healthcare NHS Trust (R.S.N., O.M., V.S.-C., A.S., E.O., I.G., P.M.); Department of Neurology (E.E.R., E.S.), King's College Hospital, London, UK; Department of Neurosciences, Drug and Child Health (A.M.), University of Florence, Italy; Barts Health NHS Trust (B.T.); Department of Haematological Medicine (V.M., M.A.K.), King's College Hospital NHS Foundation Trust; Queen Square MS Centre (O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK; Department of Health Sciences (DISSAL) (M.P.S.), University of Genova; and IRCCS Ospedale Policlinico San Martino (M.P.S.), Genova, Italy.
Paolo MuraroFrom the Department of Brain Sciences (R.S.N., A.M., A.S., P.M.), Faculty of Medicine, and Centre for Haematology (E.O., I.G.), Faculty of Medicine, Imperial College London; Imperial College Healthcare NHS Trust (R.S.N., O.M., V.S.-C., A.S., E.O., I.G., P.M.); Department of Neurology (E.E.R., E.S.), King's College Hospital, London, UK; Department of Neurosciences, Drug and Child Health (A.M.), University of Florence, Italy; Barts Health NHS Trust (B.T.); Department of Haematological Medicine (V.M., M.A.K.), King's College Hospital NHS Foundation Trust; Queen Square MS Centre (O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK; Department of Health Sciences (DISSAL) (M.P.S.), University of Genova; and IRCCS Ospedale Policlinico San Martino (M.P.S.), Genova, Italy. p.muraro@imperial.ac.uk.ORCID 0000-0002-3822-1218
London Group on Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
Imperial College Healthcare NHS Trust · GB
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine outcomes in people with multiple sclerosis (PwMS) treated with autologous hematopoietic stem cell transplantation (AHSCT) in a real-world setting.
methodsThis was a retrospective cohort study of PwMS treated with AHSCT at 2 centers in London, UK, consecutively between 2012 and 2019 who had ≥6 months of follow-up or died at any time. Primary outcomes were survival free of multiple sclerosis (MS) relapses, MRI new lesions, and worsening of Expanded Disability Status Scale (EDSS) score. Adverse events rates were also examined.
resultsThe cohort includes 120 PwMS; 52% had progressive MS (primary or secondary) and 48% had relapsing-remitting MS. At baseline, the median EDSS score was 6.0; 90% of the evaluable cases showed MRI activity in the 12 months preceding AHSCT. Median follow-up after AHSCT was 21 months (range 6-85 months). MS relapse-free survival was 93% at 2 years and 87% at 4 years after AHSCT. No new MRI lesions were detected in 90% of participants at 2 years and in 85% at 4 years. EDSS score progression-free survival (PFS) was 75% at 2 years and 65% at 4 years. Epstein-Barr virus reactivation and monoclonal paraproteinemia were associated with worse PFS. There were 3 transplantation-related deaths within 100 days (2.5%), all after fluid overload and cardiac or respiratory failure.
conclusionsEfficacy outcomes of AHSCT in this real-world cohort are similar to those reported in more stringently selected clinical trial populations, although the risks may be higher. CLASSIFICATION OF EVIDENCE: This study is rated Class IV because of the uncontrolled, open-label design.
Indexed as
Treatment OutcomeAdultCohort StudiesFemaleHematopoietic Stem Cell TransplantationHumansLondonMaleMiddle AgedMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis, Relapsing-RemittingRetrospective StudiesTransplantation, Autologous
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.